NCT04844385 2024-02-09
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
Clinical Trials
215 trialsNCT05980689 2024-02-07
Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05737563 2024-01-23
Escape
Sun Yat-sen University
Phase 3 Unknown
NCT06202014 2024-01-19
Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT06194981 2024-01-12
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
The First Affiliated Hospital of Zhengzhou University
Unknown
NCT05859477 2024-01-02
NIVOFGFR2
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT06169202 2023-12-13
A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
China Medical University, China
Unknown
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT03729687 2023-11-30
LARCT-US
Uppsala University
Phase 2 Unknown
NCT05262335 2023-11-28
ALTER-G-001
Ruijin Hospital
Phase 2 Unknown
NCT05512520 2023-11-18
EC-CRT-003
Sun Yat-sen University
Phase 2 Unknown
NCT04310176 2023-11-13
REVOLUTION
National Cancer Institute, Naples
Phase 2 Unknown
NCT05307198 2023-10-10
RAIC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT00958737 2023-09-29
IDEA
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Unknown
NCT04259944 2023-09-28
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Unknown
NCT05176964 2023-09-25
Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer
Fujian Medical University Union Hospital
Unknown
NCT05415917 2023-08-22
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Rutgers, The State University of New Jersey
Phase 2 Unknown
NCT04262687 2023-08-18
POCHI
Federation Francophone de Cancerologie Digestive
Phase 2 Unknown
NCT05974059 2023-08-03
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04262635 2023-08-02
C-CLASSIC
Sun Yat-sen University
Phase 3 Unknown
NCT03950154 2023-08-01
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT04250948 2023-08-01
Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT02560298 2023-06-22
InterAACT
Eastern Cooperative Oncology Group
Phase 2 Unknown
NCT04083365 2023-05-31
PANDORA
AUSL Romagna Rimini
Phase 2 Unknown
NCT05799820 2023-05-25
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT02288195 2023-05-12
CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients
Sun Yat-sen University
Phase 3 Unknown
NCT05815303 2023-04-18
XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT01898104 2023-03-24
V-shoRT-R3
National Cancer Institute, Naples
Phase 1/2 Unknown
NCT05732493 2023-02-17
TORCH-C
Fudan University
Phase 2 Unknown
NCT05659290 2023-01-06
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT03775525 2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1 Unknown
NCT05608785 2022-11-08
Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes
Henan Cancer Hospital
Phase 1/2 Unknown
NCT05566743 2022-10-04
A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
Menoufia University
Phase 2 Unknown
NCT05545436 2022-09-22
Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT04782804 2022-08-18
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
Fudan University
Phase 1/2 Unknown
NCT04856761 2022-08-18
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Fudan University
Unknown
NCT04866108 2022-08-18
A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy
Beijing Friendship Hospital
Phase 2 Unknown
NCT05016869 2022-08-18
Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
NCT04733963 2022-07-26
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05451719 2022-07-12
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
Fudan University
Phase 2 Unknown
NCT04401709 2022-06-15
Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer
Samsung Medical Center
Phase 3 Unknown
NCT05368051 2022-05-10
Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
Beijing Friendship Hospital
Unknown
NCT05291052 2022-03-22
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04390958 2022-03-15
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
ChineseAMS
Phase 2 Unknown
NCT04119622 2022-03-11
Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer
ChineseAMS
Phase 2 Unknown
NCT04911517 2022-02-23
Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.
Beijing Friendship Hospital
Phase 2 Unknown
NCT04390945 2022-02-03
Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2 Unknown
NCT05207735 2022-01-26
SCRCA
Henan Cancer Hospital
Phase 2 Unknown
NCT05200299 2022-01-20
mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Unknown
NCT04608786 2022-01-11
A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
Lee's Pharmaceutical Limited
Phase 1 Unknown